Arrowhead Pharma Stock Price, News & Analysis

Arrowhead Pharmaceuticals (NASDAQ: ARWR) has announced its participation in two major upcoming investor conferences in June 2025. The company will present at the Jefferies Global Healthcare Conference on June 4 at 9:20 a.m. EDT, and at the 46th Annual Goldman Sachs Global Healthcare Conference on June 9 at 2:00 p.m. EDT. Both presentations will be in a fireside chat format. Interested parties can access the presentation webcasts through the Events and Presentations page in the Investors section of Arrowhead's website.

Arrowhead Pharmaceuticals (NASDAQ: ARWR) reported strong fiscal Q2 2025 results, marking significant financial and operational progress. The company posted revenue of $542.7 million, compared to no revenue in Q2 2024, and net income of $370.4 million versus a loss of $125.3 million year-over-year. Following a major licensing deal with Sarepta Therapeutics worth $825 million upfront, Arrowhead is now funded into 2028.

The FDA has accepted the NDA for plozasiran for FCS treatment, with a PDUFA date of November 18, 2025. The company's financial position strengthened with total cash resources reaching $1.1 billion as of March 31, 2025. Additionally, CFO Ken Myszkowski will retire, to be succeeded by Daniel Apel effective May 13, 2025.

Arrowhead Pharmaceuticals (NASDAQ: ARWR) has announced its participation in two major investor conferences in May 2025. The company will present at the BofA Securities 2025 Health Care Conference on May 14, 2025, at 11:20 a.m. PDT, and at the 2025 RBC Capital Markets Global Healthcare conference on May 20, 2025, at 2:35 p.m. EDT. Both presentations will be in a fireside chat format and webcasts will be accessible through the Events and Presentations page in the Investors section of Arrowhead's website.

Arrowhead Pharmaceuticals (NASDAQ: ARWR) has scheduled its fiscal 2025 second quarter financial results webcast and conference call for May 12, 2025, at 4:30 p.m. ET. The presentation will cover financial performance for the quarter ended March 31, 2025.

Investors can access the live audio webcast through the Events and Presentations page in the Investors section of the Arrowhead website. A replay option will be available approximately two hours after the call concludes.

For analysts interested in participating in the conference call, registration is required at the provided media server link. Upon registration, participants will receive a personalized PIN code and dial-in number for call access.

Arrowhead Pharmaceuticals (NASDAQ: ARWR) announced a key leadership transition, with Daniel Apel appointed as the new Chief Financial Officer, effective May 13, 2025. He will succeed Ken Myszkowski, who is retiring after 16 years with the company. Myszkowski will remain as an employee adviser to ensure a smooth transition.

Apel joins Arrowhead from Walgreens Boots Alliance, where he served as Global Head of Financial Planning and Analysis (2019-2024). His extensive experience includes nearly 20 years at Bayer, where he held positions as CFO of Bayer U.S. (2016-2019) and CFO of Bayer Canada. The transition comes as Arrowhead prepares for its planned launch of plozasiran this year, pending regulatory approval, marking the company's shift from development to commercial stage.

Arrowhead Pharmaceuticals (NASDAQ: ARWR) has announced the approval of inducement grants for 21 new employees by its Board of Directors on April 3, 2025. The grants, approved under NASDAQ Listing Rule 5635(c)(4), collectively provide up to 34,190 restricted stock units to the new hires. These equity awards are structured outside the company's stockholder-approved equity incentive plans and feature a four-year annual vesting schedule.

Arrowhead Pharmaceuticals (NASDAQ: ARWR) has announced topline results from Part 2 of its Phase 1/2 study of ARO-C3, an RNAi therapeutic targeting complement component 3 (C3) for complement-mediated diseases. The study focused on patients with IgA nephropathy (IgAN).

Key findings from the trial (n=14) include:

• Mean sustained C3 reduction >87% through week 24
• Mean sustained AH50 reduction >76% through week 24
• Mean sustained Wieslab AP reduction >89% through week 24
• Mean reduction in spot UPCR of 41% by week 24, with maximum individual reduction of 89%

The treatment was generally well-tolerated with no serious adverse events reported. The most common side effects were headache, cough, and nasopharyngitis. The duration of effect supports quarterly or less frequent subcutaneous dosing in future studies. Additional results will be presented at a medical meeting in 2025.

Arrowhead Pharmaceuticals (NASDAQ: ARWR) presented preclinical data for two first-in-class RNAi-based therapeutics for obesity treatment: ARO-INHBE and ARO-ALK7. Both candidates target fat storage pathways while potentially preserving lean muscle mass better than current obesity therapies.

Key preclinical results showed:

• ARO-INHBE achieved 19% body weight reduction and 22% fat mass reduction in mice
• ARO-ALK7 demonstrated 39% body weight reduction and 50% fat mass reduction
• Both treatments improved liver fat accumulation
• Combination with tirzepatide showed enhanced benefits

Phase 1/2 clinical trials are underway, with ARO-INHBE dosing initiated in December 2024 and initial data expected by end of 2025. ARO-ALK7 dosing is anticipated to begin in Q2 2025, with preliminary data expected by year-end 2025.

Arrowhead Pharmaceuticals (NASDAQ: ARWR) has expanded its 'We'll Get There Soon' campaign on Rare Disease Day with new patient-centric resources for Familial Chylomicronemia Syndrome (FCS). The initiative includes the launch of www.LowerMyTGs.com, a dedicated educational website, and the release of the 'Spotlight on FCS' white paper.

FCS is an ultra-rare genetic disorder affecting 1-13 people per million globally, impairing the body's ability to process triglycerides. Patients typically experience dangerously high triglyceride levels exceeding 880 mg/dL, increasing the risk of acute pancreatitis. Expert guidelines recommend maintaining levels below 500 mg/dL.

The new resources, developed in collaboration with the FCS Foundation, Action FCS, and FH Europe Foundation, provide educational content, patient testimonials, and community connection opportunities. The initiative aims to amplify patient voices and address the underdiagnosis of FCS while supporting those affected by extremely high triglycerides.